Nanoparticles in ocular drug delivery systems for topical administration: Promises and challenges

Current Pharmaceutical Design

Volumn 21, Issue 36, 2015, Pages 5212-5224

  Almeida, Hugo ^a   Amaral, Maria Helena ^a   Lobão, Paulo ^a   Frigerio, Christian ^a,b   Lobo, José Manuel Sousa ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b Laboratori Derivati Organici   (Italy)

Author keywords

Chitosan; Colloidal dispersions; Eye drops; Lipids; Nanoparticles; Ocular; Polymers

Indexed keywords

EYE DROPS; NANOPARTICLE; POLYMER; DRUG; DRUG CARRIER; LIPID;

CHEMICAL COMPOSITION; COLLOID; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG TISSUE LEVEL; HUMAN; HYDROGEL; INTRAOCULAR DRUG ADMINISTRATION; LACRIMAL FLUID; OCULAR TISSUE; PRIORITY JOURNAL; REACTION TIME; REVIEW; STATIC ELECTRICITY; SURFACE CHARGE; TOPICAL DRUG ADMINISTRATION; BIOAVAILABILITY; CHEMISTRY; EYE; MEDICINAL CHEMISTRY; METABOLISM; PROCEDURES;

ADMINISTRATION, OPHTHALMIC; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EYE; HUMANS; LIPIDS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; POLYMERS;

EID: 84947968734     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150923095155     Document Type: Review

References (224)

1. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 2005; 57: 1595-639.
2. Pijls RT, Sonderkamp T, Daube GW, et al. Studies on a new device for drug delivery to the eye. Eur J Pharm Biopharm 2005; 59: 283- 8.
3. Pignatello R, Puglisi G. Nanotechnology in ophthalmic drug delivery systems: a survey of recent developments and patenting activity. Recent Pat Nanomed 2011; 1: 42-54.
4. Almeida H, Amaral MH, Lobão P, et al. In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug Discov Today 2014; 19: 400-12.
5. Morrison PW, Khutoryanskiy VV. Advances in ophthalmic drug delivery. Ther Deliv 2014; 5: 1297-315.
6. Gaudana R, Jwala J, Baddu SH. et al. Recent perspectives in ocular drug delivery. Pharm Res 2009; 26: 1197-216.
7. Almeida H, Amaral MH, Lobão P, et al. Applications of lipid and polymeric nanoparticles in ophthalmic pharmaceutical formulations: present and futures considerations. J Pharm Pharm Sci 2014; 17: 278-93.
8. Wu Y, You J, Zhou J, et al. Enhanced and sustained topical ocular delivery of cuclosporine A in thermosensitive hyaluronic acid based in situ forming microgels. Int J Nanomed 2013; 8: 3587-601.
9. Almeida H, Amaral MH, Lobão P, et al. Applications of poloxamers in ophthalmic pharmaceutical formulations: an overview. Expet Opin Drug Deliv 2013; 10: 1223-37.
10. Boddu SH, Gupta H, Patel S. Drug delivery to the back of the eye following topical administration: an update on research and patenting activity. Recent Pat Drug Deliv Formul 2014; 8: 27-36.
11. Khare A, Grover K, Pawar P, et al. Mucoadhesive polymers for enhancing retention in ocular drug delivery: a critical review. Rev Adhesion Adhesives 2014; 2: 467-502.
12. Hathout RM, Omran MK. Gelatin-based particulate systems in ocular drug delivery. Pharm Dev Technol Available online 8 January 2015; [Epub ahead of print].
13. Sasaki H, Yamamura K, Nishida K, et al. Delivery of drugs to the eye by topical application. Prog Ret Eye Res 1996; 15: 583-620.
14. Diebold Y, Jarrin M, Saez V, et al. Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials 2007; 28: 1553-64.
15. Motwani SK, Chopra S, Talegaonkar S, et al. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 2008; 68: 513-25.
16. Araújo J, Gonzalez E, Egea MA, et al. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomedicine 2009; 5: 394-401.
17. Seyfoddin A, Shaw J, Al-Kassas R. Solid lipid nanoparticles for ocular drug delivery. Drug Deliv 2010; 17: 467-89.
18. Nirmal HB, Bakliwal SR, Pawar SP. In-situ gel: new trends in controlled and sustained drug delivery system. Int J PharmTech Res 2010; 2: 1398-408.
19. Agarwal KI, Mehta N, Namdev A, et al. In-situ gel formation for ocular drug delivery system an overview. Asia J Bio Pharm Sci 2011; 1: 1-7.
20. Agrawal V, Gupta V, Ramteke S, et al. Preparation and evaluation of tubular micelles of pluronic lecithin organogel for transdermal delivery of sumatropin. AAPS Pharm SciTech 2010; 11: 1718-25.
21. Champalal KD, Sushilkumar P. Current status of ophthalmic in-situ forming hydrogel. Int J Pharm Bio Sci 2012; 3: 372-88.
22. Achouri D, Alhanout K, Piccerelle P, et al. Recent advances in ocular drug delivery. Drug Dev Ind Pharm 2013; 39: 1599-617.
23. Li J, Wu L, Wu W, et al. A potential carrier based on liquid crystal nanoparticles for ophthalmic delivery of pilocarpine nitrate. Int J Pharm 2013; 455: 75-84.
24. Li X, Zhang Z, Chen H. Development and evaluation of fast forming nano-composite hydrogel for ocular delivery of diclofenac. Int J Pharm 2013, 448: 96-100.
25. Ako-Adounvo AM, Nagarwal RC, Oliveira L, et al. Recent patents on ophthalmic nanoformulations and therapeutic implications. Recent Pat Drug Deliv Formul 2014; 8: 193-201.
26. Horvát G, Gyarmati B, Berkó S, et al. Thiolated poly(aspartic acid) as potential in situ gelling, ocular mucoadhesive drug delivery system. Eur J Pharm Sci 2015; 67: 1-11.
27. Meisner D, Mezei M. Liposome ocular delivery systems. Adv Drug Deliv Rev 1995; 16: 75-93.
28. Mohanambal E, Arun k, Abdul Hasan Sathali A. Formulation and evaluation of pH-triggered in situ gelling system of levofloxacin. Indian J Pharm Educ Res 2011; 45: 58-64.
29. Zimmer A, Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev 1995; 16: 61-73.
30. Zignani M, Tabatabay C, Gurny R. Topical semi-solid drug delivery: kinetics and tolerance of ophthalmic hydrogels. Adv Drug Deliv Rev 1995; 16: 51-60.
31. Järvinen K, Järvinen T, Urtti A. Ocular absorption following topical delivery. Adv Drug Deliv Rev 1995; 16: 3-19.
32. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006; 58: 1131-5.
33. Li N, Zhuang C, Wang M, et al. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int J Pharm 2009; 379: 131-8.
34. Li G, Li M. Preparation and evaluation of ophthalmic thermosensitive in situ gels of penciclovir. J Chinese Pharm Sci 2007; 16: 90-5.
35. Araújo J, Veja E, Lopes C, et al. Effect of polymer viscosity on physicochemical properties and ocular tolerance of FB-loaded PLGA nanospheres. Colloids Surf B Biointerfaces 2009; 72: 48-56.
36. Bhattarai N, Gunn J, Zhang M. Chitosan-based hydrogels for controlled, localized drug delivery. Adv Drug Deliv Rev 2010; 62: 83- 99.
37. Diebold Y, Calonge M. Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 2010; 29: 596-609.
38. Gan L, Wang J, Jiang M, et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov Today 2013; 18: 290-97.
39. Leonardi A, Bucolo C, Drago F, et al. Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabit. Int J Pharm 2015; 478: 180-6.
40. Balasubramaniam J, Kant S, Pandit JK. In vitro and in vivo evaluation of the Gelrite gellan gum-based ocular delivery system for indomethacin. Acta Pharm 2003; 53: 251-61.
41. st ed. Lisboa: Fundação Calouste Gulbenkian 2002.
42. st ed. Philadelphia: Lippincott Williams & Wilkins 2006.
43. th ed. Philadelphia: Lippincott Williams & Wilkins 2011.
44. Shen J, Deng Y, Jin X, et al. Thiolated nanostructured lipid carriers as a potential ocular delivery system for cyclosporine A: improving in vivo ocular distribution. Int J Pharm 2010; 402: 248-53.
45. Shen J, Wang Y, Ping Q, et al. Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J Control Release 2009; 137: 217-23.
46. Wang F, Chen L, Zhang D, et al. Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the treatment of glaucoma: vitro and vivo study. J Drug Target 2014; 22: 849-56.
47. Pignatello R, Bucolo C, Spedalieri G, et al. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 2002; 23: 3247-55.
48. Bonferoni MC, Sandri G, Gavini E, et al. Microparticle systems based on polymer drug interaction for ocular delivery of ciprofloxacin I. In vitro characterization. J Drug Deliv Sci Tech 2007; 17: 57-62.
49. Gan L, Han S, Shen J, et al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability. Int J Pharm 2010; 396: 179-87.
50. Müller RH, Shegokar R, Keck CM 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr Drug Discov Technol 2011; 8: 207-27.
51. Moya-Ortega MD, Alves TFG, Alvarez-Lorenzo C, et al. Dexamethasone eye drops containing γ-cyclodextrin-based nanogels. Int J Pharm 2013; 41: 507-51.
52. Ribeiro A, Sandez-Macho I, Casas M, et al. Poloxamine micellar solubilization of α-tocopherol for topical ocular treatment. Colloids Surf B Biointerfaces 2013; 103: 550-7.
53. Agrawal V, Kumar M, Pathak K. Defining the properties of pH - sensitive polymeric micellar ocular delivery system of miconazole nitrate for the management of fungal endophthalmitis. Pharm Nanotechnol 2014; 2: 157-66.
54. Pignatello R, Leonardi A, Cupri S. Optimization and validationof a new method for the production of lipid nanoparticles for ophthalmic application. Int J Med Nano Res 2014; 1: 1-6.
55. Fangueiro JF, Silva AM, Garcia ML et al. Current nanotechnology approaches for the treatment and management of the diabetic retinopathy. Eur J Pharm Biopharm 2014; [Epub ahead of print].
56. Fresta M, Panico AM, Bucolo C, et al. Characterization and in-vivo ocular absorption of liposome-encapsulated acyclovir. J Pharm Pharmacol 1999; 51: 565-67.
57. Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today 2008; 13: 144-51.
58. Nagarwal RC, Kant S, Singh PN, et al. Polymeric nanoparticulate system: A potential approach for ocular drug delivery. J Control Release 2009; 136: 2-13.
59. Nagarwal RC, Kumar R, Pandit JK. Chitosan coated sodium alginate- chitosan nanoparticles loaded with 5-FU for ocular delivery: in vitro characterization and in vivo study in rabbit eye. Eur J Pharm Sci 2012; 47: 678-85.
60. Bhatta RS, Chandasana H, Chhonker YS, et al. Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: in vitro and pharmacokinetics studies. Int J Pharm 2012; 432: 105-12.
61. Land MF, Fernald RD. The Evolution of Eyes. Annu Rev Neurosci 1992; 15: 1-29.
62. Raviola G. The structural basis of the blood-ocular barriers. Exp Eye Res 1977; 25: 27-63.
63. Rolando M, Zierhut M. The ocular surface and tear film and their dysfunction in dry eye disease. Surv Ophthalmol 2001; 45: S203- 10.
64. Presland A, Myatt J. Ocular anatomy and physiology relevant to anaesthesia. Anaesth Intens Care Med 2010; 11: 438-43.
65. Malhotra A, Minja FJ, Crum A, et al. Ocular anatomy and crosssectional imaging of the eye. Semin Ultrasound CT MRI 2011; 32: 2-13.
66. Bourlais CL, Acar L, Zia H, et al. Ophthalmic drug delivery systems: recent advances. Prog Retin Eye Res 1998; 17: 33-58.
67. Patil BB, Dowd TC. Physiological functions of the eye. Curr Anaesth Crit Care 2000; 11: 293-8.
68. Smerdon D. Anatomy of the eye and orbit. Curr Anaesth Crit Care 2000; 11: 286-92.
69. De la Fuente, Raviña M, Paolicelli P, et al. Chitosan-based nanostructures: A delivery platform for ocular therapeutics. Adv Drug Deliv Rev 2010; 62: 100-17.
70. El-Kamel AH. In vitro an in vivo evaluation of Pluronic F127- based ocular delivery system for timolol maleate. Int J Pharm 2002; 241: 47-55.
71. Baeyens V, Percicot C, Zignani M, et al. Ocular drug delivery in veterinary medicine. Adv Drug Deliv Rev 1997; 28: 335-61.
72. Baeyens V, Gurny R. Chemical and physical parameters of tears relevant for the design of ocular drug delivery formulations. Pharm Acta Helv 1997; 72: 191-202.
73. Xinming L, Yingde C, Lloyd AW, et al. Polymeric hydrogels for novel contact lens-based ophthalmic drug delivery systems: a review. Cont Lens Anterior Eye 2008; 31: 57-64.
74. Suresh PK, Sah AK. Nanocarriers for ocular delivery for possible benefits in the treatment of anterior uveitis: focus on current paradigms and future directions. Expert Opin Drug Deliv 2014; 11: 1- 22.
75. Greaves JL, Olejnik O, Wilson CG. Polymers and the precorneal tear film. STP Pharma Sci 1992; 2: 13-33.
76. Romanelli L, Valeri P, Morrone LA, et al. Ocular absorption and distribution of bendazac after topical administration to rabbits with different vehicles. Life Sci 1994; 54: 877-85.
77. Carvalho IM, Marques CS, Oliveira RS, et al. Sustained drug release by contact lenses for glaucoma treatment-A review. J Control Release 2015; 202: 76-82.
78. Robinson JR. Ocular drug delivery. Mechanism of corneal drug transport and mucoadhesive delivery systems. STP Pharma 1989; 5: 839-46.
79. Edsman K, Carlfors J, Petersson R. Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. Eur J Pharm Sci 1998; 6: 105-12.
80. Abdel-Mottaleb MMA, Mortada ND, Elshamy AA, et al. Preparation and evaluation of fluconazole gels, egypt. J Biomed Sci 2007; 23: 266-86.
81. Robinson JR, Mlynek GM. Bioadhesive and phase-change polymers for ocular drug delivery. Adv Drug Deliv Rev 1995; 16: 45- 50.
82. Sandri G, Bonferoni MC, Rossi S, et al. Platelet lysate formulations based on mucoadhesive polymers for the treatment of corneal lesions. J Pharm Pharmacol 2011; 63: 189-98.
83. Geethalakshmia A, Karkib R, Sagib P, et al. Temperature triggered in situ gelling system for betaxolol in glaucoma. J App Pharm Sci 2013; 3: 153-9.
84. Patel GC, Dalwadi CA. Recent patents on stimuli responsive hydrogels drug delivery systems. Recent Pat Drug Deliv Formul 2013; 7: 206-15.
85. Caló E, Khutoryanskiy VV. Biomedical applications of hydrogels: A review of patents and commercial products. Eur Polym J 2015; 65: 252-67.
86. Sandri G, Bonferoni MC, Rossi S, et al. Thermosensitive eyedrops containing platelet lysate for the treatment of corneal ulcers. Int J Pharm 2012; 426: 1-6.
87. Başaran E, Yenilmez E, Berkman MS, et al. Chitosan nanoparticles for ocular delivery of cyclosporine A. J Microencapsul 2014; 31: 49-57.
88. Wilson CG. Topical drug delivery in the eye. Exp Eye Res 2004; 78: 737-43.
89. Wu C, Qi H, Chen W, et al. Preparation and evaluation of a Carbopol/ HPMC-based in situ gelling ophthalmic system for puerarin. Yakugaku Zasshi 2007; 127: 183-91.
90. Lee CH, Moturi V, Lee Y. Thixotropic property in pharmaceutical formulations. J Control Release 2009; 136: 88-98.
91. You J, Almeda D, Ye GJC, et al. Bioresponsive matrices in drug delivery. J Biol Eng 2010; 4: 1-12.
92. El-Bagory IM, Bayomi MA, Mahrous GM, et al. Effect of gamma irradiation on pluronic gels for ocular delivery of ciprofloxacin: in vitro evaluation. Aust J of Basic Appl Sci 2010; 4: 4490-8.
93. Rupenthal ID, Green CR, Alany RG. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 1: physicochemical characterisation and in vitro release. Int J Pharm 2011; 411: 69-77.
94. Tayel SA, El-Nabarawi MA, Tadros MI, et al. Promising ionsensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride: Design, in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits. Int J Pharm 2013; 443: 293-305.
95. Yu S, Wang Q, Wang X, et al. Liposome incorporated ion sensitive in situ gels for ophthalmic delivery of timolol maleate. Int J Pharm 2015; 480: 128-36.
96. Almeida H, Amaral MH, Lobão P, et al. Pluronic® F-127 and pluronic lecithin organogel (PLO): main features and their applications in topical and transdermal administration of drugs. J Pharm Pharm Sci 2012; 15: 592-605.
97. Sandri G, Bonferoni MC, Chetoni P, et al. Ophthalmic delivery systems based on drug-polymer-polymer ionic ternary interaction: in vitro and in vivo characterization. Eur J Pharm Biopharm 2006; 62: 59-69.
98. Bawa P, Pillay V, Choonara YE, et al. Stimuli-responsive polymers and their applications in drug delivery. Biomed Mater 2009; 4: 1- 15.
99. Desai SD, Blanchard J. Evaluation of Pluronic F 127-based sustained- release ocular delivery systems for pilocarpine using the albino rabbit eye model. J Pharm Sci 1998; 87: 1190-5.
100. Miyazaki S, Suzuki S, Kawasaki N, et al. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int J Pharm 2001; 229: 29-36.
101. Wei G, Xu H, Ding PT, et al. Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies. J Control Release 2002; 83: 65-74.
102. Qi H, Li L, Huang C, et al. Optimization and physicochemical characterization of thermosensitive poloxamer gel containing puerarin for ophthalmic use. Chem Pharm Bull 2006; 54: 1500-7.
103. Qi H, Chen W, Huang C, Li L, et al. Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int J Pharm 2007; 337: 178-87.
104. Mansour M, Mansour S, Mortada ND, et al. Ocular poloxamerbased ciprofloxacin hydrochloride in situ forming gels. Drug Dev Ind Pharm 2008; 34: 744-52.
105. Mayol L, Quaglia F, Borzacchiello A, et al. A novel poloxamers/ hyaluronic acid in situ forming hydrogel for drug delivery: rheological, mucoadhesive and in vitro release properties. Eur J Pharm Biopharm 2008; 70: 199-206.
106. Varshosaz J, Tabbakhian M, Salmani Z. Designing of a thermoreversible chitosan/poloxamer in situ gel for ocular delivery of ciprofloxacin. Open Drug Deliv J 2008; 2: 61-70.
107. Mohan EC, Kandukuri JM, Allenki V. Preparation and evaluation of in-situ-gels for ocular drug delivery. J Pharm Res 2009; 2: 1089- 94.
108. Shastri DH, Patel LD, Parikh RK. Studies on in situ hydrogel: a smart way for safe and sustained ocular drug delivery. J Young Pharm 2010; 2: 116-20.
109. Shastri DH, Prajapati ST, Patel LD. Thermoreversible mucoadhesive ophthalmic in situ hydrogel: design and optimization using a combination of polymers. Acta Pharm 2010; 60: 349-60.
110. Gupta S, Samanta MK, Raichur AM. Dual-drug delivery system based on in-situ gel-forming nanosuspension of forskolin to enhance antiglaucoma efficacy. AAPS PharmSciTech 2010; 11: 322- 35.
111. Vodithala S, Khatry S, Shastri N, et al. Development and evaluation of thermoreversible ocular gels of ketorolac tromethamine. Int J Biopharm 2010; 1: 39-45.
112. Ammar HO, Salama HA, Ghorab M, et al. Development of dorzolamide hydrochloride in situ gel nanoemulsion for ocular delivery. Drug Dev Ind Pharm 2010; 36: 1330-9.
113. Darwhekar G, Jain P, Jain DK, et al. Development and optimization of dorzolamide hydrochloride and timolol maleate in situ gel for glaucoma treatment. Asian J Pharm Ana 2011; 1: 93-7.
114. He Z, Wang Z, Zhang H, et al. Doxycycline and hydroxypropyl-bcyclodextrin complexin poloxamer thermal sensitive hydrogel for ophthalmic delivery. Acta Pharmaceut Sin B 2011; 1: 254-60.
115. Gratieri T, Gelfuso GM, Rocha EM, et al. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur J Pharm Biopharm 2010; 75: 186-93.
116. Leszczyńka K, Namiot A, Cruz K, et al. Potential of ceragenin CSA- 13 and its mixture with pluronic F127 as treatment of topical bacterial infections. J Appl Microbiol 2011; 110: 229-38.
117. Bankhele SC, Harale RB, Rao MRP, et al. Thermoreversible in-situ ophthalmic gelling system of levofloxacin hemihydrate: formulation and optimization by factorial design. Asian J Pharm Res 2012; 2: 100-6.
118. Dilbaghi N. Kaur H. Ahuja M. et al. Evaluation of tropicamideloaded tamarind seed xyloglucan nanoaggregates for ophthalmic delivery. Carbohydr Polym 2013; 94: 286-91.
119. Matanović MR, Kristl J, Grabnar PA. Thermoresponsive polymers: Insights into decisive hydrogel characteristics, mechanisms of gelation, and promising biomedical applications. Int J Pharm 2014; 472: 262-75.
120. Genta I, Conti B, Perugini P, et al. Bioadhesive microspheres for ophthalmic administration of acyclovir. J Pharm Pharmacol 1997; 49: 737-42.
121. Felt O, Furrer P, Mayer JM, et al. Topical use of chitosan in ophthalmology: tolerance, assessment and evaluation of precorneal retention. Int J Pharm 1999; 180: 185-93.
122. Li J, Xu Z. Physical characterization of a chitosan-based hydrogel delivery system. J Pharm Sci 2002; 91: 1669-77.
123. Gupta H, Aqil M, Khar RK, et al. Development and characterization of Tc-99m timolol maleate for evaluating efficacy of in situ ocular drug delivery system. AAPS Pharm Sci Tech 2009; 10: 540- 6.
124. Schoenwald RD, Ward RL, DeSantis LM, et al. Influence of highviscosity vehicles on miotic effect of pilocarpine. J Pharm Sci 1978; 69: 1280-3.
125. Kumar S, Haglund BO, Himmelstein KJ. In situ-forming gels for ophthalmic drug delivery. J Ocul Pharmacol 1995; 10: 47-56.
126. Kumar S, Himmelstein KJ. Modification of in situ gelling behavior of carbopol solutions by hydroxypropyl methyl cellulose. J Pharm Sci 1995; 84: 344-8.
127. Oechsner M, Keipert S. Polyacrylic acid/polyvinylpyrrolidone bipolymeric systems. I. Rheological and mucoadhesive properties of formulations potentially useful for the treatment of dry-eyesyndrome. Eur J Pharm Biopharm 1999; 47: 113-8.
128. Hartmann V, Keipert S. Physico-chemical, in vitro and in vivo characterization of polymers for ocular use. Pharmazie 2000; 55: 440-3.
129. Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Release 2001; 73: 205-11.
130. Gil ES, Hudson SM. Stimuli-responsive polymers and their bioconjugates. Prog Polym Sci 2004; 29: 1173-222.
131. Wu H, Liu Z, Peng J, et al. Design and evaluation of baicalincontaining in situ pH-triggered gelling system for sustained ophthalmic drug delivery. Int J Pham 2011; 410: 31-40.
132. Durrani AM, Davies NM, Thomas M, et al. Pilocarpine bioavailability from a mucoadhesive liposomal ophthalmic drug delivery system. Int J Pharm 1992; 88: 409-15.
133. Lehr CM, Yong HL, Lee VHL. Improved ocular penetration of gentamicin by mucoadhesive polymer polycarbophil in the pigmented rabbit. Invest Ophthalmol Vis Sci 1994; 35: 2809-14.
134. Nagarsenker MS, Londhe VY, Nadkarni GD. Preparation of liposomal formulation of tropicamide for ocular delivery. Int J Pharm 1999; 190: 63-71.
135. Shen Y, Ling X, Jiang W, et al. Formulation and evaluation of Cyclosporin A emulgel for ocular delivery. Drug Deliv 2015; 22(7): 911-7.
136. Gurny R, Boye T, Ibrahim H. Ocular therapy with nanoparticulate systems for controlled drug delivery. J Control Release 1985; 2: 353-61.
137. Gurny R. Preliminary study of prolonged acting drug delivery systems for the treatment of glaucoma. Pharm Acta Helv 1981; 156: 130-2.
138. Trinquand C, Romanet JP, Nordmann JP, et al. Efficacite et tolerance du carteolol 1% liberation prolongee une fois par jour. J Fr Ophthalmol 2003; 26: 131-6.
139. Ahuja N, Saini V, Bishnoi VK, et al. Formulation and evaluation of diclofenac sodium gel by using natural polymer. Rasayan J Chem 2008; 1: 564-6.
140. Carlfors J, Edsman K, Petersson R, et al. Rheological evaluation of Gelrite® in situ gels for ophthalmic use. Eur J Pharm Sci 1998; 6: 105-12.
141. Paulsson M, Hägerström H, Edsman K. Rheological studies of the gelation of deacetylated gellan gum (Gelrite®) in physiological conditions. Eur J Pharm Sci 1999; 9: 99-105.
142. Duan Y, Cai X, Du H, et al. Novel in situ gel systems based on P123/TPGS mixed micelles and gellan gum for ophthalmic delivery of curcumin. Colloids and Surfaces B: Biointerfaces 2015; 128: 322-30.
143. Almeida H, Amaral MH, Lobão P, et al. Influence of drug incorporation, temperature and storage time on the pH, textural and rheological properties of different poloxamer hydrogels. Curr Drug Deliv 2013; 10: 753-64.
144. Lin HR, Sung KC. Carbopol/Pluronic phase change solutions for ophthalmic drug delivery. J Control Release 2000; 69: 379-88.
145. Lin HR, Sung KC, Vong WJ. In situ gelling of alginate/pluronic solutions for ophthalmic delivery of pilocarpine. Biomacromolecules 2004; 5: 2358-65.
146. Gupta H, Jain S, Mathur R, et al. Sustained ocular drug delivery from a temperature and ph triggered novel in-situ gel system. Drug Deliv 2007; 14: 507-15.
147. Gupta S, Vyas SP. Carbopol/chitosan based pH triggered in situ gelling system for ocular delivery of timolol maleate. Sci Pharm 2010; 78: 959-76.
148. Asasutjarit R, Thanasanchokpibull S, Fuongfuchat A, et al. Optimization and evaluation of thermoresponsive diclofenac sodium ophthalmic in situ gel. Int J Pharm 2011; 411: 128-35.
149. Yeole PG, Iyer D. Thermosensitive in situ gel of Timolol Maleate for the treatment of open angle glaucoma. Res J Pharm Biol Chem Sci 2011; 2: 1048-64.
150. Rathman G. Sustained ophthalmic delivery of atenolol for Glaucoma by in situ gelling system. Int J Pharm Res Dev 2012; 4: 291- 301.
151. Wagh VD, Deshmukh KH, Wagh KV. Formulation and evaluation of in situ gel drug delivery system of sesbania grandiflora flower extract for the treatment of bacterial conjunctivitis. J Pharm Sci Res 2012; 4: 1880-4.
152. Gupta H, Aquil M, Khar RK, et al. An alternative in situ gelformulation of levofloxacin eye drops for prolong ocular retention. J Pharm Bioallied Sci 2015; 7: 9-14.
153. Bochot A, Fattal E, Grossiord JL, et al. Characterization of a new ocular delivery system based on a dispersion of liposomes in a thermosensitive gel. Int J Pharm 1998; 162: 119-27.
154. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54: S131- 55.
155. Olbrich C, Scholer N, Tabatt K, et al. Cytotoxicity studies of Dynasan 114 solid lipid nanoparticles (SLN) on RAW 264.7 macrophages- impact of phagocytosis on viability and cytokine production. J Pharm Pharmacol 2004; 56: 883-91.
156. Kaur IP, Garg A, Singla AK. et al. Vesicular systems in ocular drug delivery: an overview. Int J Pharm 2004; 269: 1-14.
157. Müller-Goymann CC. Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharm 2004; 58: 343-56.
158. Souto EB, Müller RH. Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J Microencapsul 2006; 23: 377-88.
159. Huang ZR, Hua SC, Yang YL. et al. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol Sin 2008; 29: 1094-102.
160. Gokce EH, Sandri G, Bonferoni MC, et al. Cyclosporine A loaded SLNs: Evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm 2008; 364: 76-86.
161. Doktorovova S, Gokce E, Ozyazici M, et al. Lipid matrix nanoparticles. Pharmacokinetics and biopharmaceutics. Curr Nanosci 2009; 5: 358-71.
162. Souto EB, Müller RH. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handb Exp Pharmacol 2010; 197: 115-41.
163. Araújo J, Gonzalez-Mira E, Egea MA, et al. Optimization and physicochemical characterization of a triamcinolone acetonideloaded NLC for ocular antiangiogenic applications. Int J Pharm 2010; 393: 167-75.
164. Souto EB, Doktorovova S, Gonzalez-Mira E, et al. Feasibility of Lipid Nanoparticles for Ocular Delivery of Anti-inflammatory Drugs. Curr Eye Res 2010; 35: 537-52.
165. Luo Q, Zhao J, Zhang X, et al. Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 2011; 403: 185-91.
166. Jain GK, Pathan SA, Akhter S, et al. Microscopic and spectroscopic evaluation of novel PLGA-chitosan nanoplexes as an ocular delivery system. Colloids Surf B Biointerfaces 2011; 82: 397: 403.
167. Silva AC, Amaral MH, González-Mira E, et al. Solid lipid nanoparticles (SLN)-based hydrogels as potential carriers for oral transmucosal delivery of risperidone: preparation and characterization studies. Colloids Surf B Biointerfaces 2012; 93: 241-8.
168. Sarmento, BFCC. Improvement of peptidic drugs oral availability through their encapsulation in polyelectrolytes complexes. Tese de Doutoramento em Ciências Farmacêuticas. Porto: Faculdade de Farmácia da Universidade do Porto 2007.
169. Silva AC, Santos D, Ferreira D, et al. Advances in nanoparticulate carriers for oral peptides and proteins: polymeric vs. lipid nanoparticles. Encyclopedia of Nanoscience and Nanotechnology. Los Angeles, California: American Scientific Publishers 2010.
170. Silva AC, González-Mira E, García ML, et al. Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): High pressure homogenization versus ultrasound. Colloids Surf B Biointerfaces 2011; 86: 158-65.
171. Gonzalez-Mira E, Egea MA, Garcia ML, et al. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf B Biointerfaces 2010; 81: 412-21.
172. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001; 47: 165- 96.
173. Fangueiro JF, Andreani T, Egea MA, et al. Experimental factorial design applied to mucoadhesive lipid nanoparticles via multiple emulsion process. Colloids Surf B Biointerfaces 2012; 100: 84-9.
174. Fangueiro JF, Andreani T, Egea MA, et al. Design of cationic lipid nanoparticles for ocular delivery: Development, characterization and cytotoxicity. Int J Pharm 2014; 461: 64-73.
175. Fangueiro JF, Andreani T, Fernandes L, et al. Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation. Colloids Surf B Biointerfaces 2014; 123: 452-60.
176. Jores K, Mehnert W, Drechsler M, et al. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field flow fractionation and transmission electron microscopy. J Control Release 2004; 95: 217-27.
177. Souto EB, Doktorovova S. Chapter 6 - solid lipid nanoparticle formulations: pharmacokinetic and biopharmaceutical aspects in drug delivery. Methods Enzymol 2009; 464: 105-29.
178. Műller RH, Maassen S, Weyhers H, et al. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target 1996; 4: 161-70.
179. Wake MC, Gerecht PD, Lu L, et al. Effects of biodegradable polymer particles on rat marrow-derived stromal osteoblasts in vitro. Biomaterials 1998; 19: 1255-68.
180. Ravi Kumar MNV, Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci 2000; 3: 234-58.
181. De Campos AM, Diebold Y, Carvalho EL, et al. Chitosan nanoparticles as new ocular drug delivery systems: In vitro stability, in vivo fate, and cellular toxicity. Pharm Res 2004; 21: 803-10.
182. Kao HJ, Lin HR, Lo YL, et al. Characterization of pilocarpineloaded chitosan/carbopol nanoparticles. J Pharm Pharmacol 2006; 58: 179-86.
183. Gupta H, Aqil M, Khar RK, et al. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine 2010; 6: 324-33.
184. Gupta H, Aqil M, Khar RK, et al. Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery. J Drug Target 2011; 19: 409-17.
185. Gupta H, Aqil M, Khar RK, et al. Nanoparticles laden in situ gel for sustained ocular drug delivery. J Pharm Bioalled Sci 2013; 5: 162-5.
186. Gupta H, Aqil M, Khar RK, et al. Nanoparticles laden in situ gel of levofloxacin for enhanced ocular retention. Drug Deliv 2013; 20: 306-9.
187. Silva NC, Silva S, Sarmento B, et al. Chitosan nanoparticles for daptomycin delivery in ocular treatment of bacterial endophthalmitis. Drug Deliv 2015; 22(7): 885-93.
188. Silva AC, González-Mira E, Lobo JM, et al. Current progresses on nanodelivery systems for the treatment of neuropsychiatric diseases: Alzheimer's and schizophrenia. Curr Pharm Des 2013; 19: 7185-95.
189. Chockalingam V, Bandaru BR, Senthilkumar K. et al. Chitosan nanoparticles as vehicle for prolonged ocular delivery of ofloxacin. Pharm Nanotechnol 2014; 2: 149-56.
190. Mahmoud AA, El-Feky GS, Kamel R, et al. Chitosan/ sulfobutylether-β-cyclodextrin nanoparticles as a potential approach for ocular drug delivery. Int J Pharm 2011; 413: 229-36.
191. Kumar R, Nagarwal RC, Dhanawat M, et al. In vitro and in vivo study of indomethacin loaded gelatin nanoparticles. J Biomed Nanotechnol 2011; 7: 325-33.
192. Nagarwal RC, Kumar R, Dhanawat M, et al. Modified PLA nano in situ gel: a potential ophthalmic drug delivery system. Colloids Surf B Biointerfaces 2011; 86: 28-34.
193. Li F, Hurley B, Liu Y, et al. Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration. Open Ophthalmol J 2012; 6: 54-58.
194. Varshochian R, Jeddi-Tehrani M, Mahmoudi AR, et al. The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments. Eur J Pharm Sci 2013; 50: 341-52.
195. De Campos AM, Sánchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm 2001; 224: 159-68.
196. Abrego G, Alvarado H, Souto EB, et al. Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration. Eur J Pharm Biopharm 2015; [Epub ahead of print].
197. Doktorovova S, Souto EB. Nanostructured lipid carrier-based hidrogel formulations for drug delivery: a comprehensive review. Expert Opin Drug Deliv 2009; 6: 165-75.
198. Jenning V, Gysler A, Schafer-Korting M, et al. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm 2000; 49: 211-8.
199. Jenning V, Schafer-Korting M, Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: active release properties. J Control Release 2000; 66: 115-26.
200. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-77.
201. Cavalli R, Gasco MR, Chetoni P, et al. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 2002; 238: 241-5.
202. Ugazio E, Cavalli R, Gasco MR. Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int J Pharm 2002; 241: 341-4.
203. Attama AA, Reichl S, Műller-Goymann CC. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm 2008; 355: 307-13.
204. Li X, Nie SF, Kong J, et al. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm 2008; 363: 177-82.
205. Kalam MA, Sultana Y, Ali A, et al. Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system. J Drug Target 2010; 18: 191- 204.
206. Silva AC, Kumar A, Wild W, et al. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles. Int J Pharm 2012; 436: 798-805.
207. Silva AC, Santos D, Ferreira D, et al. Lipid-based Nanocarriers as an Alternative for Oral Delivery of Poorly Water- Soluble Drugs: Peroral and Mucosal Routes. Curr Med Chem 2012; 19: 4495-510.
208. Araújo J, Nikolic S, Egea MA, et al. Nanostructured lipid carriers for triamcinolone acetonide delivery of the posterior segment of the eye. Colloids Surf B Biointerfaces 2011; 88: 150-7.
209. Seyfoddin A, Al-Kassas R. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev Ind Pharm 2012; 39: 508-19.
210. Tian BC, Zhang WJ, Xu HM, et al. Further investigation of nanostructured lipid carriers as an ocular delivery system: in vivo transcorneal mechanism and in vitro release study. Colloids Surf B Biointerfaces 2013; 102: 251-6.
211. Finke JH, Schmolke H, Klages CP, et al. Controlling solid lipid nanoparticle adhesion by polyelectrolyte multilayer surface modifications. Int J Pharm 2013; 449: 59-71.
212. Chakraborty S, Shukla D, Mishra B, Singh S. Lipid-an emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm 2009; 73: 1-15.
213. Mendes AI, Silva AC, Catita JAM, et al. Miconazole-loaded nanostructured lipid carriers (NLC) for local delivery to the oral mucosa: Improving antifungal activity. Colloids Surf B Biointerfaces 2013; 111: 755-63.
214. Liu Z, Zhang X, Wu H, et al. Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo. Drug Dev Ind Pharm 2011; 37: 475-81.
215. Gonzalez-Mira E, Nikolic S, Calpena AC, et al. Improved and safe transcorneal delivery of flurbiprofen by NLC and NLC based hydrogels. J Pharm Sci 2012; 101: 707-25.
216. Hao J, Wang X, Bi Y, et al. Fabrication of a composite system combining solid lipid nanoparticles and thermosensitive hydrogel for challenging ophthalmic drug delivery. Colloids Surf B Biointerfaces 2014; 114: 111-20.
217. Roy I, Gupta MN. Smart polymeric materials: emerging biochemical applications. Chem Biol 2003; 10: 1161-71.
218. Joshi M, Patravale V. Formulation and evaluation of Nanostructured lipid carrier (NLC)-based gel of Valdecoxib. Drug Dev Ind Pharm 2006; 32: 911-8.
219. Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm 2008; 346: 124-32.
220. Casadei MA, Cerreto F, Cesa S, et al. Solid lipid nanoparticles incorporated in dextran hydrogels: a new drug delivery system for oral formulations. Int J Pharm 2006; 325: 140-6.
221. Bajpai AK, Shukla SK, Bhanu S, et al. Responsive polymers in controlled drug delivery. Prog Polym Sci 2008; 33: 1088-118.
222. Teeranachaideekul V, Souto EB, Muller RH, et al. Physicochemical characterization and in vitro release studies of ascorbyl palmitate- loaded semi-solid nanostructured lipid carriers (NLC gels). J Microencapsul 2008; 25: 111-20.
223. Bhaskar K, Krishna MC, Lingam M, et al. Development of SLN and NLC enriched hydrogels for transdermal delivery of nitrendipine: in vitro and in vivo characteristics. Drug Dev Int Pharm 2009; 35: 98-113.
224. Puglia C, Offerta A, Carbone C, et al. Lipid nanocarriers (LNC) and their applications in ocular drug delivery. Curr Med Chem 2015; 22: 1-14.